Alzheimer’s disease is an irreversible, progressive brain disorder that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks. In most people with the disease—those with the late-onset type—symptoms first appear in their mid-60s. Early-onset Alzheimer’s occurs between a person’s 30s and mid-60s and is very rare. Alzheimer’s disease is the most common cause of dementia among older adults.
DelveInsight’s, “Alzheimer’s Disease Pipeline Insights, 2021,” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Alzheimer’s Disease (AD) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Get free sample report: https://www.delveinsight.com/sample-request/alzheimers-disease-ad-pipeline-insight
Some of Alzheimer’s Disease Companies:
Alzheimers Disease Symptoms
Alzheimer’s disease is a progressive condition therefore the symptoms get worse over time. Memory loss is a key feature, and this tends to be one of the first symptoms to develop.
Other symptoms are:
Later symptoms include impaired communication, disorientation, confusion, poor judgment, behavioral changes and, ultimately, difficulty speaking, swallowing and walking.
As the disease progresses, neurons in other parts of the brain are damaged or destroyed.
Some of Alzheimers Disease Therapies:
Table of Contents:
Introduction
Executive Summary
Alzheimer’s Disease (AD): Overview
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
Alzheimer’s Disease (AD) – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Alzheimer’s Disease (AD) Collaboration Deals
Late Stage Products (Phase III)
BAN2401: Eisai
Mid Stage Products (Phase II)
Bryostatin-1: Neurotrope
Early Stage Products (Phase I)
INB03 – INmune Bio
Pre-clinical and Discovery Stage Products
AZT-211: AZTherapies
Inactive Products
Alzheimer’s Disease (AD) Key Companies
Alzheimer’s Disease (AD) Key Products
Alzheimer’s Disease (AD)- Unmet Needs
Alzheimer’s Disease (AD)- Market Drivers and Barriers
Alzheimer’s Disease (AD)- Future Perspectives and Conclusion
Alzheimer’s Disease (AD) Analyst Views
Appendix
Request for Detailed TOC: https://www.delveinsight.com/sample-request/alzheimers-disease-ad-pipeline-insight
About DelveInsight DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Ankit NigamEmail: Send EmailPhone: +19193216187Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/sample-request/alzheimers-disease-ad-pipeline-insight